Stockscreener 앱 받기
5.08
2.79%
0.07
전일 마감가:
$5.01
열려 있는:
$5.01
하루 거래량:
22,458
Relative Volume:
1.21
시가총액:
$55.47M
수익:
-
순이익/손실:
$-33.82M
주가수익비율:
-0.1916
EPS:
-26.5174
순현금흐름:
$-66.04M
1주 성능:
-5.50%
1개월 성능:
+4.25%
6개월 성능:
-41.87%
1년 성능:
-0.77%
1일 변동 폭
$5.01
$5.4781
1주일 범위
$4.90
$5.54
52주 변동 폭
$2.96
$11.45
Elicio Therapeutics Inc Stock (ELTX) Company Profile
명칭
Elicio Therapeutics Inc
전화
(857) 209-0050
주소
451 D STREET, 5TH FLOOR, BOSTON
ELTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| ELTX | 5.14 | 55.47M | 0 | -33.82M | -66.04M | -26.52 |
| VRTX | 449.08 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.10 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 595.35 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.78 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.14 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Elicio Therapeutics Inc 주식(ELTX)의 최신 뉴스
Elicio Therapeutics: Q3 Earnings Snapshot - mySA
Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewswire
Elicio Therapeutics adjourns annual meeting due to lack of quorum - Investing.com
Elicio reports promising Phase 1 cancer vaccine trial results - Investing.com India
Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting - GlobeNewswire
Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study - The Bakersfield Californian
Elicio Therapeutics adjourns annual meeting due to lack of quorum By Investing.com - Investing.com UK
Jones Trading Initiates Coverage of Elicio Therapeutics (ELTX) with Buy Recommendation - MSN
Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit - The Manila Times
Elicio Therapeutics to Present Clinical Data at the Society - GlobeNewswire
All You Need to Know About Elicio Therapeutics (ELTX) Rating Upgrade to Strong Buy - Yahoo Finance
Elicio Therapeutics announces new CFO and accounting officer By Investing.com - Investing.com Australia
Elicio Therapeutics announces new CFO and accounting officer - Investing.com
Elicio Therapeutics reports inducement grants - TipRanks
Elicio Therapeutics Reports Inducement Grants - GlobeNewswire
Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted - The Bakersfield Californian
Elicio Therapeutics Announces Three Upcoming Presentations - GlobeNewswire
Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines - StockTitan
KalVista Appoints Brian Piekos as Chief Financial Officer - Business Wire
Elicio Therapeutics CFO resigns to pursue new opportunity By Investing.com - Investing.com Australia
Elicio Therapeutics CFO resigns to pursue new opportunity - Investing.com
Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewswire
ELTX Stock Earnings: Elicio Therapeutics Beats EPS for Q2 2024 - InvestorPlace
Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note - GlobeNewswire
Elicio Therapeutics’ US$40 Million ATM and US$11.5 Million Public Offering - Global Legal Chronicle
Therapeutic Vaccine Industry to Witness Massive Growth - openPR
ASCO 2024Chris Haqq - pharmaphorum
Ratios in Focus: Analyzing Elicio Therapeutics Inc. (ELTX)'s Price-to-Cash and Price-to-Free Cash Flow – DWinneX - The Dwinnex
Why Is Cancer Vaccine Developer Elicio Therapeutics Stock Trading Lower On Friday? - MSN
Elicio Therapeutics sets $11.5 million stock offering By Investing.com - Investing.com Australia
Orion Group Holdings inks $30.5M land sale deal By Investing.com - Investing.com
Apple shares target raised, reiterates Outperform on AI potential By Investing.com - Investing.com
Elicio Therapeutics Shares Drop 35% After Public Offering Prices - MarketWatch
Elicio Therapeutics Prices of $11.5 Million Underwritten Public Offering - citybiz
Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering - GlobeNewswire
Why Is Elicio Therapeutics (ELTX) Stock Down 36% Today? - InvestorPlace
Elicio Therapeutics launches public offering of stock and warrants By Investing.com - Investing.com Australia
Elicio reports promising early results in cancer vaccine trial By Investing.com - Investing.com Australia
Elicio Therapeutics Inc (ELTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):